Login to Your Account

FDA stand on tivo CRC biomarker reshuffles Aveo's priorities

By Marie Powers
News Editor

Friday, June 12, 2015

The roller-coaster ride that is Aveo Oncology Inc. took another dip Friday when the company reported written feedback from the FDA on the development of a biomarker that would help predict the response of patients with colorectal cancer to tivozanib compared with Avastin.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription